HGH Fragment 176-191
C-terminal fragment of human growth hormone (residues 176-191) for lipolysis, fat oxidation, and adipocyte metabolism research.
Select size
For research purposes only. Not for human consumption.
Mechanism of Action
HGH Fragment 176-191 is the unmodified C-terminal 16-amino acid fragment of human growth hormone (residues 176-191). It retains the lipolytic and anti-lipogenic activity of full-length hGH while lacking the growth-promoting, insulin-resistance, and IGF-1-mediated effects.
How It Works
- 1
Stimulates lipolysis (breakdown of stored triglycerides) in adipose tissue
- 2
Inhibits lipogenesis — reduces conversion of dietary carbohydrate into newly stored fat
- 3
Engages beta-3 adrenergic receptor pathways on adipocytes to mobilize free fatty acids
- 4
Does not bind the growth hormone receptor — no effect on IGF-1, glucose, or insulin sensitivity in research models
- 5
Short plasma half-life supports tightly controlled dosing studies
Key Research Benefits
- Targeted adipose lipolysis research
- Fat oxidation and energy expenditure studies
- No IGF-1 or glucose metabolism interference
- Cleaner mechanistic profile than full-length hGH
- Adjunct to GLP-1 and lipotropic stack protocols
HGH Fragment 176-191 is the parent peptide that AOD-9604 was modified from (AOD-9604 adds an N-terminal tyrosine for stability). It is widely used in adipose-tissue, body-composition, and lipid-metabolism research where isolation of the lipolytic domain of hGH is required. Strictly research use only — not for human or veterinary administration.